Sarah E. McClelland

EXO1 inhibition selectively kills replication repair-deficient cancer cells

Abstract Deficiencies in DNA repair pathways create context-specific vulnerabilities that may be exploited therapeutically. Recent studies have established EXO1 as a druggable nuclease, but the genetic contexts that confer sensitivity to EXO1 inhibition remain incompletely defined. Here, we assessed whether pharmacolog...